Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Campus Vienna Biocenter - Progress on Alzheimer’s Vaccine

16.09.2005


An innovative vaccination can significantly reduce deposits of the substances in the brain responsible for causing Alzheimer’s disease. This result was disclosed today by Affiris GmbH, a company located at the Campus Vienna Biocenter, Austria. The rapid progress during the pre-clinical development phase has already enabled the Vienna-based company, although having operated only since April 2004, to plan clinical trials for 2006, and thus proves the international competitiveness of the Campus Vienna Biocenter.



Beta-amyloids are pathological fragments of a normal brain protein. They are responsible for the development of Alzheimer’s disease, as they cause the death of brain cells. Amyloid fragments are found in large amounts in the cerebral fluid of Alzheimer patients. Deposits are formed in the brain over the years, thus creating the plaque structures typical of Alzheimer’s disease. It has not yet been completely clarified whether plaque formation or the soluble beta-amyloids are the causative agents for Alzheimer’s disease.

Tailor-made Vaccine


The Vienna-based company Affiris is now reporting that it has succeeded in significantly reducing Alzheimer plaques by at least two-thirds in pre-clinical models by means of an innovative vaccine. CEO Dr. Walter Schmidt explains the important feature of the vaccination strategy: "Alzheimer’s is caused by a fragment of one of the ubiquitous proteins of cerebral cells. If one wants to combat Alzheimer immunologically it is essential to generate antibodies which are targeted against the beta-amyloids, but which leave the normal constituent of the cerebral cells unharmed, since the latter would induce an autoimmune disease. In keeping with this, Affiris´ vaccine approach has been shown to be highly specific for beta amyloids and not to react with the normal constituent of cerebral cells."

Thus, the Affiris approach not only avoids an autoimmune disease, but also offers the advantage of targeting simultaneously both the plaques and the soluble beta-amyloid fraction. Therefore, whether the soluble or plaque forms - or both - are responsible for causing the disease is not ultimately crucial for the vaccine’s success. The additional proof that the vaccine induces antibodies, which are active against plaques in human tissue samples, and the first data collected on the toxicology profile have further contributed to built a secure basis for Affiris to schedule the first trials on patients for 2006.

Biotech with Economics

Beside its scientific success Affiris also boasts important economic advantages: low costs and short manufacturing times for its vaccine. In the words of Dr. Schmidt: "Our substances are produced at low costs and a building-block system is used to form the vaccine. The effective component is synthetically manufactured and combined with a carrier substance isolated from natural resources. Both together form the actual vaccine and a standard adjuvant is added to strengthen the immune response."

The fact that the management has taken these important economic aspects into consideration from the very beginning is also due to the comprehensive biotech experiences at the Campus Vienna Biocenter. After all, numerous biotech companies and research institutes are situated at the Campus Vienna Biocenter, in addition to the FH Campus Wien (biotechnology), the Life Science Departments of the University of Vienna and the Medical University of Vienna, all sharing both resources and experiences and thus contributing to the international success of this location.

About AFFiRiS (September 2005):

AFFiRiS develops peptide-based vaccines for the treatment of Alzheimer’s disease and atherosclerosis. The company has established platform technologies and registered seven patents. 12 employees work in a 6,500 sqf rented laboratory facility on the Campus Vienna Biocenter.

About the Campus Vienna Biocenter (September 2005):

The Campus Vienna Biocenter is one of the largest R&D clusters in Austria with approx. 1,000 scientists from 40 nations at 16 organisations. Academic departments (University of Vienna, Medical University of Vienna, subsumed in the Max F. Perutz Laboratories), private research institutes (IMP - Institute of Molecular Pathology) and institutes of the Austrian Academy of Sciences (IMBA - Institute of Molecular Biotechnology, GMI - Gregor Mendel Institute) are also located here along with commercial R&D companies, service companies and training course centres.

Till C. Jelitto | alfa
Further information:
http://www.prd.at
http://www.affiris.com
http://www.viennabiocenter.com

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>